Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by LEO Pharma

< Previous 1 2 Next >
LEO Pharma Strengthens Leadership in Medical Dermatology with the Appointment of Sophie Lamle as Chief Development Officer
From LEO Pharma
Via Business Wire
LEO Pharma Reinforces Leadership in Medical Dermatology with New Data from Across Its Portfolio at 2025 Fall Clinical Dermatology Conference
From LEO Pharma
Via Business Wire
LEO Pharma Closes Deal for Spevigo®
From LEO Pharma
Via Business Wire
LEO Pharma Presents Late-Breaking Data at EADV 2025 Showing Week 16 Tralokinumab Response Predicts Long-Term Response in Moderate-to-Severe Atopic Dermatitis
From LEO Pharma
Via Business Wire
LEO Pharma presents two late-breaking abstracts for temtokibart reporting positive Phase 2b efficacy, safety and biomarker results in moderate-to-severe atopic dermatitis at the 2025 EADV Annual Meeting in Paris
From LEO Pharma
Via Business Wire
LEO Pharma Takes Centre Stage With its Largest-Ever Scientific Programme at EADV 2025
From LEO Pharma
Via Business Wire
LEO Pharma Delivers 7% Revenue Growth at CER in H1 2025 and Achieves Key Milestones Enabling Future Growth
From LEO Pharma
Via Business Wire
Boehringer Ingelheim and LEO Pharma Enter Partnership to Commercialize and Further Develop SPEVIGO® (spesolimab)
From LEO Pharma
Via Business Wire
LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates for Systemic Therapy
From LEO Pharma
Via Business Wire
LEO Pharma Initiates Phase 2a DELTA NEXT Trial of Delgocitinib Cream in Adults with Mild to Severe Palmoplantar Pustulosis (PPP)
From LEO Pharma
Via Business Wire
Three-month interim report (Q1) 2025 (Unaudited): LEO Pharma Delivers 9% Revenue Growth at Constant Exchange Rates and Doubles Adjusted EBITDA Margin to 16%
From LEO Pharma
Via Business Wire
To Sharpen Focus on the Global Commercialization of Strategic Products and the External Partnership Model, LEO Pharma Makes Changes to Leadership
From LEO Pharma
Via Business Wire
LEO Pharma Survey: Dermatology Providers Agree Chronic Hand Eczema Impacts Patients’ Emotional, Social and Occupational Well-Being
From LEO Pharma
Via Business Wire
LEO Pharma Meets Primary Endpoint in Phase 3 DELTA China Trial with Anzupgo® (delgocitinib) Cream in Chinese Patients with Moderate to Severe Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
LEO Pharma Delivers Double-Digit Revenue Growth and Strong Progress for Strategic Transformation
From LEO Pharma
Via Business Wire
LEO Pharma Achieves Positive DELTA TEEN Trial Results with Anzupgo® (delgocitinib) Cream in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
MHRA Grants Marketing Authorisation for LEO Pharma’s Anzupgo® ▼(delgocitinib) cream in Great Britain
From LEO Pharma
Via Business Wire
LEO Pharma’s Anzupgo® (delgocitinib) Cream Achieves Marketing Approval in Switzerland
From LEO Pharma
Via Business Wire
LEO Pharma Continues to Deliver Double-Digit Revenue Growth Backed by Strong Dermatology Sales
From LEO Pharma
Via Business Wire
Germany Becomes the First Country to Launch LEO Pharma’s Anzupgo® (delgocitinib) Cream
From LEO Pharma
Via Business Wire
LEO Pharma Commits to Net-Zero Greenhouse Gas Emissions by 2050
From LEO Pharma
Via Business Wire
LEO Pharma Presents Late-breaking Tralokinumab Data at EADV 2024 for Moderate-to-Severe Atopic Dermatitis (AD) in the Difficult-to-Treat Head and Neck Region
From LEO Pharma
Via Business Wire
LEO Pharma Submits New Drug Application for Enstilar® for Adults with Plaque Psoriasis in China
From LEO Pharma
Via Business Wire
LEO Pharma Presents Late-Breaking Results from the Phase 2a Mechanism of Action Trial of Temtokibart and Dupilumab in Moderate-to-Severe Atopic Dermatitis at the 2024 EADV Annual Meeting
From LEO Pharma
Via Business Wire
LEO Pharma Presents Late-Breaking Anzupgo® (delgocitinib) Cream Presentation at EADV 2024 Highlighting Results of Head-to-Head DELTA FORCE Trial in Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
LEO Pharma Unveils Most Extensive EADV Program To Date with 5 Late Breaking Abstracts and 23 Posters Sharing Clinical and Real-World Data
From LEO Pharma
Via Business Wire
European Commission Approves LEO Pharma’s Anzupgo® (delgocitinib) Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE)
From LEO Pharma
Via Business Wire
FDA Accepts LEO Pharma’s Filing of Delgocitinib Cream New Drug Application for the Treatment of Chronic Hand Eczema
From LEO Pharma
Via Business Wire
LEO Pharma Presents Data from the Largest-Ever Multinational Real-World Studies of Chronic Hand Eczema (CHE) in Adults at the ESCD 2024 Congress
From LEO Pharma
Via Business Wire
LEO Pharma Delivers 11% Revenue Growth (CER) in H1 and Upgrades Financial Outlook for the Year
From LEO Pharma
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.